Christiansen, Sara NysomHorskjær Rasmussen, SimonPons, MarionMichelsen, BrigitteGlintborg, BenteGuðbjörnsson, BjörnGröndal, Gerður MaríaVencovsky, JiriLoft, Anne GitteRotar, ZigaPirkmajer, Katja PerdanNissen, Michael JBaranová, JanaMacfarlane, Gary JJones, Gareth TIannone, FlorenzoCaporali, RobertoLaas, KarinVorobjov, SigridGiuseppe, Daniela DiOlofsson, TorProvan, Sella AarrestadFagerli, Karen MindeCastrejon, IsabelOtero-Varela, Luciavan de Sande, Marleenvan der Horst-Bruinsma, IreneNordström, DanKuusalo, LauraBernardes, MiguelHetland, Merete LundØstergaard, MikkelMidtbøll Ørnbjerg, Lykke2025-11-202025-11-202024-04Christiansen, S N, Horskjær Rasmussen, S, Pons, M, Michelsen, B, Glintborg, B, Guðbjörnsson, B, Gröndal, G M, Vencovsky, J, Loft, A G, Rotar, Z, Pirkmajer, K P, Nissen, M J, Baranová, J, Macfarlane, G J, Jones, G T, Iannone, F, Caporali, R, Laas, K, Vorobjov, S, Giuseppe, D D, Olofsson, T, Provan, S A, Fagerli, K M, Castrejon, I, Otero-Varela, L, van de Sande, M, van der Horst-Bruinsma, I, Nordström, D, Kuusalo, L, Bernardes, M, Hetland, M L, Østergaard, M & Midtbøll Ørnbjerg, L 2024, 'Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice', Seminars in Arthritis and Rheumatism, vol. 65, 152388, pp. 152388. https://doi.org/10.1016/j.semarthrit.2024.1523880049-0172217471728142bf78b-441f-4298-8743-6d1d108d05e33830134985184021202unpaywall: 10.1016/j.semarthrit.2024.152388https://hdl.handle.net/20.500.11815/7478Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.OBJECTIVES: In patients with axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA) initiating secukinumab, we aimed to assess and compare the proportion of patients achieving 6-, 12- and 24-month patient-reported outcomes (PRO) remission and the 24-month retention rates. PATIENTS AND METHODS: Patients with axSpA or PsA from 16 European registries, who initiated secukinumab in routine care were included. PRO remission rates were defined as pain, fatigue, Patient Global Assessment (PGA) ≤2 (Numeric Rating Scale (NRS) 0-10) and Health Assessment Questionnaire (HAQ) ≤0.5, for both axSpA and PsA, and were calculated as crude values and adjusted for drug adherence (LUNDEX). Comparisons of axSpA and PsA remission rates were performed using logistic regression analyses (unadjusted and adjusted for multiple confounders). Kaplan-Meier plots with log-rank test and Cox regression analyses were conducted to assess and compare secukinumab retention rates. RESULTS: We included 3087 axSpA and 3246 PsA patients initiating secukinumab. Crude pain, fatigue, PGA and HAQ remission rates were higher in axSpA than in PsA patients, whereas LUNDEX-adjusted remission rates were similar. No differences were found between the patient groups after adjustment for confounders. The 24-month retention rates were similar in axSpA vs. PsA in fully adjusted analyses (HR [95 %CI] = 0.92 [0.84-1.02]). CONCLUSION: In this large European real-world study of axSpA and PsA patients treated with secukinumab, we demonstrate for the first time a comparable effectiveness in PRO remission and treatment retention rates between these two conditions when adjusted for confounders.2416396152388eninfo:eu-repo/semantics/openAccessBiologic therapyClinical study in epidemiologyCohort studyRheumatic diseasesSpondyloarthritisAntibodies, Monoclonal, HumanizedPainHumansTreatment OutcomeAxial SpondyloarthritisArthritis, Psoriatic/drug therapyAnesthesiology and Pain MedicineRheumatology/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article10.1016/j.semarthrit.2024.152388